A new treatment, CT041, is bringing hope to patients with advanced pancreatic cancer. This therapy uses modified T-cells to target cancer cells and has shown encouraging results. In a recent study, patients who received CT041 had a median overall survival of 10 months.
Despite some side effects like blood-related issues and digestive problems, the therapy was generally well-tolerated. Out of 24 patients, 70.8% saw their disease controlled, and many experienced a significant reduction in cancer markers.
While these results are promising, more research is needed to fully understand the benefits. If you or a loved one has advanced pancreatic cancer, discuss new treatment options with your doctor.
Read the full article here
Leave a Reply